Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter
NARMAFOTINIB Large-Scale Manufactre CompleteSuccessful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers SymposiumMelbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason Lickliter will present a poster at the forthcoming ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026, in San Francisco. The poster, titled Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results, will present updated data from the ongoing ACCENT trial. The full abstract will be published 5pm US ET, January 5th, 2026. The details for the poster presentation are shown below.
